Kaul Inderjit, a director at Minerva Neurosciences, Inc., has exercised stock options for 2,328 shares of the company's common stock. This transaction occurred on November 2, 2026, and was reported in a recent SEC filing.

Minerva Neurosciences, based in Burlington, Massachusetts, focuses on developing innovative treatments for neuropsychiatric diseases. The company is particularly known for its work in the pharmaceutical preparations sector, with a strong emphasis on advancing its clinical trials.

The filing reveals that Inderjit acquired the shares at an exercise price of $2.345 per share. Additionally, the option has specific vesting conditions: 25% will vest on November 14, 2026, with further vesting contingent on the company achieving significant trial milestones related to its treatment for schizophrenia.

“25% of the option shall vest on November 14, 2026; an additional 45% shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia.”

This move may influence other stakeholders within Minerva, particularly those involved in the ongoing Phase 3 trial of roluperidone, a treatment aimed at addressing schizophrenia. The successful development and approval of this treatment could have significant implications for the company and its standing within the pharmaceutical industry.

The filing does not specify what will happen next regarding Inderjit's stock options or any upcoming announcements from Minerva Neurosciences.